Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt

Alnylam Pharmaceuticals Inc. said a phase 3 trial for one of its drugs would continue, potentially easing investor concerns over the safety of its portfolio.

Source: WSJ.com: Health - October 10, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news